Zhejiang Huahai Pharmaceutical Co (SHSE:600521) Valuation Rank

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:600521 Zhejiang Huahai Pharmaceutical Co Ltd SHSE:600521
84 GF Score
Price ¥16.01
GF Value ¥16.46
Valuation Fairly Valued
! 8 Warning Signs
View Full Analysis

What is Zhejiang Huahai Pharmaceutical Co Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Zhejiang Huahai Pharmaceutical Co Valuation Rank Related Terms

SHSE:600521
84GF Score
Zhejiang Huahai Pharmaceutical Co Ltd SHSE:600521
Valuation Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Zhejiang Huahai Pharmaceutical Co (SHSE:600521) Overvalued in 2026?

Based on GuruFocus' analysis, Zhejiang Huahai Pharmaceutical Co stock appears to be undervalued. The current stock price of ¥16.01 is trading 2.7% below its estimated GF Value™ of ¥16.46. GuruFocus considers Zhejiang Huahai Pharmaceutical Co to be Fairly Valued.

Key valuation signals for SHSE:600521:

  • Valuation Rank:
  • GF Value™: ¥16.46 vs. price of ¥16.01 (2.7% below fair value)
  • GF Score™: 84/100 with 8 warning signs

No single metric tells the full story. See the SHSE:600521 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Zhejiang Huahai Pharmaceutical Co Business Description

Address Xunqiao, Zhejiang Province, Linhai, CHN, 317024
Zhejiang Huahai Pharmaceutical Co Ltd is engaged in research and development, production, and sales of multi-dosage preparations, biological drugs, innovative drugs, and specialty APIs. The company's products include irbesartan hydrochlorothiazide tablets, losartan potassium tablets, paroxetine hydrochloride tablets, sertraline hydrochloride tablets, linagliptin tablets, dabigatran etexilate capsules, pemetrexed disodium for injection, esomeprazole magnesium enteric-coated capsules, torsemide injection, and others.
84GF Score

Get the complete analysis for SHSE:600521

Valuation Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥16.01
Price
¥16.46
GF Value